Abstract
We report here the case of a 63-year-old man who had a diffuse large B-cell lymphoma associated with hemophagocytic syndrome (HPS). The lymphoma involved the spleen, bilateral adrenal glands, and paraaortic lymph nodes of the abdomen. In both the bone marrow and lymph nodes, hemophagocytosis was evident, and the laboratory findings were consistent with HPS. The lymphoma cells showed a CD4+, CD5+, CD10−, CD19+, CD20+, CD25+ and surface immunoglobulin µα/κ+ immunophenotype. The patient was unintentionally treated with rituximab alone, resulting in complete resolution of the lymphomatous lesions as well as the features of HPS in response to the initial two doses of rituximab, although he developed gastric hemorrhage requiring vigorous resuscitation. After the completion of eight doses of rituximab, the patient remains free of disease with an excellent performance status.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
C Shimazaki T Inaba M Nakagawa (2000) ArticleTitleB-cell lymphoma-associated hemophagocytic syndrome Leuk Lymphoma 38 121–130 Occurrence Handle10811454 Occurrence Handle1:STN:280:DC%2BD3c3mvFGqsw%3D%3D
T Murase S Nakamura K Tashiro et al. (1997) ArticleTitleMalignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis: a report of five cases and review of the literature Br J Haematol 99 656–664 Occurrence Handle9401080 Occurrence Handle10.1046/j.1365-2141.1997.4623265.x Occurrence Handle1:STN:280:DyaK1c%2Fmt1amsA%3D%3D
K Tobinai (2002) ArticleTitleMonoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan Int J Hematol 76 411–419 Occurrence Handle12512835 Occurrence Handle1:CAS:528:DC%2BD3sXlt1artQ%3D%3D
K Tobinai T Igarashi K Itoh et al. (2004) ArticleTitleJapanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma Ann Oncol 15 821–830 Occurrence Handle15111353 Occurrence Handle10.1093/annonc/mdh176 Occurrence Handle1:STN:280:DC%2BD2c3htFylsQ%3D%3D
JM Vose BK Link ML Grossbard et al. (2001) ArticleTitlePhase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 389–397 Occurrence Handle11208830 Occurrence Handle1:CAS:528:DC%2BD3MXhtVekt7o%3D
WP Schmidt N Schmitz R Sonnen (2004) ArticleTitleConservative management of gastric lymphoma: the treatment option of choice Leuk Lymphoma 45 1847–1852 Occurrence Handle15223645 Occurrence Handle10.1080/1042819042000219476
RA Popescu AC Wotherspoon D Cunningham et al. (1999) ArticleTitleSurgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: the Royal Marsden Hospital experience Eur J Cancer 35 928–934 Occurrence Handle10533473 Occurrence Handle10.1016/S0959-8049(99)00069-6 Occurrence Handle1:STN:280:DC%2BD3c%2FgtlKltA%3D%3D
DG Maloney TM Liles DK Czerwinski et al. (1994) ArticleTitlePhase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 84 2457–2466 Occurrence Handle7522629 Occurrence Handle1:STN:280:DyaK2M%2Fgt12ltg%3D%3D
D Shan JA Ledbetter OW Press (1998) ArticleTitleApoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1644–1652 Occurrence Handle9473230 Occurrence Handle1:CAS:528:DyaK1cXht12gsbk%3D
T Ohno Y Ueda K Nagai et al. (2003) ArticleTitleThe serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas Int J Hematol 77 286–294 Occurrence Handle12731674 Occurrence Handle1:CAS:528:DC%2BD3sXjslCqsro%3D Occurrence Handle10.1007/BF02983788
LE van der Kolk AJ Grillo-Lopez JW Baars et al. (2003) ArticleTitleTreatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy Leukemia 17 1658–1664 Occurrence Handle12886256 Occurrence Handle10.1038/sj.leu.2402995 Occurrence Handle1:CAS:528:DC%2BD3sXlslOisb8%3D
M Yamaguchi M Seto M Okamoto et al. (2002) ArticleTitleDe novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients Blood 99 815–821 Occurrence Handle11806981 Occurrence Handle10.1182/blood.V99.3.815 Occurrence Handle1:CAS:528:DC%2BD38XhtValsL0%3D
HS Khalidi RK Brynes P Browne et al. (1998) ArticleTitleIntravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases Mod Pathol 11 983–988 Occurrence Handle9796727 Occurrence Handle1:STN:280:DyaK1M%2FhtVOmsw%3D%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sano, T., Sakai, H., Takimoto, K. et al. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome. Int J Clin Oncol 12, 59–62 (2007). https://doi.org/10.1007/s10147-006-0627-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-006-0627-9